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Genetic markers in long term survivors of Glioblastoma Multiforme 
 
1. Introduction 
The most common type of primary brain tumour is glioblastoma multiforme or GBM, 
which accounts for around 38% of brain tumours.  It is also the most aggressive and has a 
median survival time of 14.6 months even with intensive therapy and is invariably fatal.  
GBMs have several characteristics that make them difficult to treat.  One is that their 
growth is invasive with diffuse infiltration into adjacent brain tissue.  This is unlike many 
other tumour types that initially grow within a discrete capsule.  This diffuse infiltration 
makes it impossible to remove the entire tumour surgically without removing a large area 
of healthy brain.  Another characteristic is that tumour cells accumulate mutations and 
changes in gene expression over time that make chemotherapy and radiotherapy 
treatments less effective.   
 
A subgroup of GBM patients, however, display significantly longer overall survival. This 
subgroup has been documented previously as “Long Term Survivors” (LTS) where 
patients show survival of 3 years or more after the initial diagnosis of a GBM.  Scott et al 
(1999) in a population based case control study of LTS GBM patients matched for age, 
sex and year of diagnosis with short term survivors (STS), found that LTS patients had a 
higher Karnofsky Performance Score and were more likely to have had gross total 
resection and adjuvant chemotherapy and their tumours were more likely to have fewer 
mitoses than control patients. The incidence of LTS in the GBM population is less than 
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3%.  Molecular markers that can predict which GBM patients will fall into the LTS 
category are currently unknown and need to be elucidated.  
 
A recent microarray and qPCR study in the Cancer Genetics Laboratory at the Kolling 
Institute identified two marker genes, IQGAP and IGFBP2 as being significant in 
predicting the aggressiveness of glioma tumours (McDonald et al, 2007).  In this study 
three GBM patients had survival times of over three years.  Two of these three LTSs were 
found to have low expression of IQGAP and IGFBP2 as measured by 
immunohistochemistry.  The third patient, with a survival time over 1000 days had high 
expression in these genes but had received unusually aggressive treatment at their own 
request and expense. 
 
The expression of IGFBP2 (Insulin-like Growth Factor Binding Protein 2) is increased in 
a range of tumour types, with a positive correlation between tumour grade and the level of 
expression.  However the mechanisms by which IGFBP2 is involved in tumorigenesis are 
not clear.  Wang et al (2007) found that cell lines over-expressing IGFBP2 RNA showed 
significantly enhanced invasiveness and also had increased expression of matrix 
metaloproteinase-2 (MMP-2), which plays a role in tumour progression by degrading the 
extracellular matrix. 
 
IQGAP (IQ-motif-containing GTPase activation protein 1) reduces the ability of cells to 
adhere to each other by binding to E-cadherin and preventing it from binding the catenins 
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and attaching to the actin cytoskeleton.  Hence its increased expression is associated with 
reduced cell-cell adhesion which allows cells to migrate and metastasize. 
 
Additional genes that have been found to be important in tumour progression are PTEN 
and MGMT.  PTEN (phosphatase and tensin homolog) gene, when correctly expressed, 
acts as a tumour suppressor gene by regulating cell proliferation, promoting apoptosis and 
regulating cell migration and invasion.  Mutations in the PTEN gene are responsible for 
Cowden Syndrome characterised by overgrowth of tissue.  PTEN regulates cell 
proliferation by promoting cell-cycle arrest in the G1 phase through inhibition of the 
PI3K/Akt pathway.  PTEN sensitises glioma cells to apoptosis when irradiated or treated 
with chemotherapy drugs also through the PI3K/Akt pathway.  PTEN expression reduces 
glioma cell invasion in vitro but the molecular mechanism for this is not yet fully 
understood.  The PTEN gene is often mutated to an inactive form in glioma tumours.  
PTEN is also important in controlling angiogenesis during tumour formation again 
through the PI3K/Akt pathway by regulating HIF1α and VEGF expression (Park et al, 
2002).   
 
Hegi et al (2005) found that MGMT promoter methylation as shown by methylation 
specific PCR, was a favourable prognostic factor for longer survival, irrespective of 
treatment.  The methylation of the MGMT promoter was also found to be associated with 
a more favourable response of patients to temozolomide and radiotherapy treatment.  The 
MGMT gene encodes the enzyme O-6-methylguanine-DNA methyltransferase, a DNA 
repair enzyme which removes methyl groups from the O-6 position of guanine.  
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Alkylating chemotherapy drugs such as temozolamide, act by adding methyl groups to 
DNA which then targets the cell for death by apoptosis.  So the MGMT enzyme can repair 
damage caused by chemotherapy drugs.  Methylation of promoter regions of genes 
inhibits their expression and so the methylation of the MGMT promoter region would be 
expected to result in lower expression and better tumour response to alkylating drugs.  
However MGMT plays conflicting roles in cancer since the ability of MGMT to repair 
DNA damage is vital for cell survival.  The silencing of MGMT results in an increased 
frequency of mutations which can lead to more aggressive tumour behaviour in mutated 
cells.  As a result of the paper by Hegi showing that patients with high levels of 
methylation of the MGMT gene have a better response to the temozolomide, GBM 
patients with low MGMT promoter methylation are denied temozolomide treatment in 
some parts of the world.   
 
Now a total of 13 LTSs have been identified where long term survival was defined as 
survival for more than 1000 days.  This study compared immunohistochemistry 
expression data for IQGAP and IGFBP2 in these LTSs to patients with survival times of 
less than 1000 days (STSs) to see if the observation of lower IQGAP and IGFBP2 
expression in LTSs was confirmed.  We also looked at the expression of additional genes: 
MGMT and PTEN as assessed by immunohistochemistry.  The study population were all 
consenting patients aged less than 65 years, diagnosed with GBM between January 1998 
and 31st August 2004, treated at Royal North Shore Hospital or North Shore Private 
Hospital, or by participating clinicians at the Prince of Wales Private Hospital, who 
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received the standard treatment of tumour resection, if achievable, radiotherapy and 
temozolomide chemotherapy. 
 
1.1. Aim 
The aim of this study was to determine if the expression of a range of proteins that have 
been shown to be differentially expressed in glioblastoma tissue, can be used as an aid to 
predicting survival time in patients with GBMs.  In particular, the aim was to determine 
whether long term survival, defined as survival for more than 1000 days, can be predicted 
by expression levels of any of the proteins: IGFBP2, IQGAP1 or PTEN in tumour tissue 
or by the % nuclei staining for MGMT expression. 
 
1.2. Hypotheses 
Low expression of IGFBP2 and IQGAP1 and high levels of expression of PTEN in 
samples of tumour tissue obtained at initial biopsy or surgery, as measured by 
immunohistochemistry, are predictive of survival for more than 1000 days in glioblastoma 
patients.  The hypothesis relating to MGMT expression is more complicated as this gene 
has conflicting roles in tumour development.  Because some GBM patients with 
unmethylated MGMT promoter regions are being denied temozolomide treatment, it is 
important to test the hypothesis behind this policy.  This hypothesis is that low MGMT 
expression, which is the expected result of high levels of promoter methylation, is 
associated with a better prognosis in patients receiving the standard treatment of 
radiotherapy and chemotherapy with temozolamide. 
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2. Methods: 
2.1. Patient Selection 
Patients were selected from the Neuroendocrine Tumour Bank over a seven year period 
(1998-2004) and their survival outcomes determined from the Sydney Neuroendocrine 
database.  Tumour samples and clinical data including patient age, gender, tumour 
location and treatment were obtained in Sydney under the auspices of Dr Ray Cook, a 
leading member of the Sydney Neuro-oncology Group (SNOG).  All consenting patients 
diagnosed with a GBM during this interval and aged less than 65 years, were categorised 
into two groups on the basis of their survival time: short-term survivors (STS) with 
survival times of less than 1000 days after diagnosis and long-term survivors (LTS) with 
survival times greater than 1000 days.  Age was restricted to less than 65 years as all LTSs 
were younger than this and as age over 65 is one of the most significant predictors of poor 
survival.  The census date was 30th June 2007 as this was when the immunohistochemistry 
and scoring were completed and the analysis started.  No patients diagnosed after 31st 
August 2004 were included in the study as they would not have had the opportunity to 
become a long-term survivor before the census date.  41 patients fulfilled these criteria of 
which 28 were STSs and 13 were LTSs.  At the time of the census date, four LTSs were 
still alive. 
 
An experienced neuropathologist, Dr Janice Brewer, from the Department of Anatomical 
Pathology at Royal North Shore Hospital, collected archived paraffin blocks of tumour 
tissue obtained from glioblastoma patients at the time of initial biopsy or surgery, i.e. very 
close to the time of initial diagnosis.  The tumours were diagnosed as GBMs by Dr Brewer 
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by means of histological examination of sections cut from this embedded tissue according 
to the WHO 2000 criteria.  Ethics approval for this study was covered by Protocol 0612-
228M and was obtained from the Human Research Ethics Committees of participating 
institutions.  
 
2.2. Immunohistochemistry Detection of Proteins in GBM samples 
Paraffin sections (4μm) were cut from the blocks by the Department of Anatomical 
Pathology at RNSH and immunohistochemistry was used to detect the cytoplasmic protein 
expression of IGFBP2 and IQGAP1 and PTEN and the nuclear-specific protein MGMT.  
Trained technicians, blinded to the survival-time, assessed the degree of staining. 
 
2.2.1. IGFBP2 Immunohistochemistry 
Positive IGFBP2 staining is typically observed in the cytoplasm of the tumour samples 
since it is a secreted protein. Scores were allocated to represent all observed degrees of 
staining.  Subjects were given scores between 0 and 3 for IGFBP2 staining, where 0 
represented no cytoplasmic staining, 1 for weak cytoplasmic staining (<5% of examined 
tumour cells), 2 for moderate cytoplasmic staining (<25% of examined tumour cells) and 
3 for strong membranous and cytoplasmic staining (>25% of examined tumour cells).  
 
2.2.2. IQGAP1 Immunohistochemistry 
Positive IQGAP1 staining was typically visualised as a strong cytoplasmic reaction. To 
score for IQGAP1 staining, subjects were given scores between 0 and 4 with where 0 
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represented no staining, 1 for weak cytoplasmic staining (<5% of examined tumour cells), 
2 for moderate cytoplasmic staining (<20% of examined tumour cells), 3 for moderate to 
strong cytoplasmic staining (<25% of examined tumour cells) and 4 for strong 
cytoplasmic staining (>25% of examined tumour cells).  
 
2.2.3. PTEN Immunohistochemistry 
PTEN was also localised in the cytoplasm.  The scoring for PTEN was more complex and 
staining was graded according to a previously established scale of 0-2 (Mellinghoff et al, 
2005).  A score of 2 was given when the cytoplasmic staining intensity was equal to that 
of the vascular endothelium, 1 if it was less intensely stained than the endothelium, and 0 
if it was undetectable.  Tumours with a score of 0 or 1 were then considered PTEN 
negative and a score of 2 was positive, giving a binary final score.  
 
2.2.4. MGMT Immunohistochemistry 
MGMT expression was quantified by microscopically examining 500–1000 tumour cells 
under high-power and counting cells with stained nuclei.  The percent of stained cells was 
calculated by dividing the number with stained nuclei by the number of cells counted. 
 
These IHC scoring methods were dictated by the appearance of the staining in the tissue 
being examined and was guided by previous practice in similar published studies. 
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2.3. Statistical Analyses 
Initial exploratory analysis looked at the frequencies of the categorical variables and at the 
distribution of the continuous variable, age.  The variable for percentage of nuclei staining 
for MGMT was divided into categories at the overall quartiles and treated as an ordered 
categorical variable because its distribution was highly skewed and because the most 
frequent result was zero.  As the sample size was small, Fisher’s exact test was used to test 
for significance differences between LTSs and STSs in categorical variables and the 
Mantel-Haenszel test which is also valid for small sample sizes was used to test for 
significant trends in the ordered categorical variables (Kay, 2007).  Univariate logistic 
regression was carried out to assess the linear trend of the regression coefficients for each 
level of the ordered categorical variables since the logistic regression model used for 
multivariate modelling, assumes a linear relationship between the outcome and the risk 
factor.  If there was not a linear trend, categories with similar coefficients were merged 
until a linear trend or a binary variable was achieved.  The Mann Whitney test was used to 
compare the mean age of LTSs and STSs as age was found not to be normally distributed.  
The p-values for the Mantel-Haenszel test for trend were adjusted using a modified 
Bonferroni correction as the cutpoints used had been chosen to maximise trend (Lausen 
and Schumaker, 1996). 
 
All statistical methods were carried out using the data set that included the three original 
LTSs and also on a second data set without these three patients as the presence of the 
original patients may have biased the analysis since two of the three were known to have 
low expression of IQGAP1 and IGFBP2 and including them could give a more significant 
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outcome than a sample of patients not including them.  The results for this alternative 
analysis are given in the appendix. 
 
Univariate logistic regression was used to find if the level of protein expression could be 
used to predict whether a subject would be a LTS using those genes with P < 0.25 in the 
exploratory analysis.  For those genes that were predictive of long-term survival in this 
univariate analysis, the joint effect of these genes in predicting long-term survival was 
assessed using multivariate logistic regression.  The influence of the presence of genes on 
the size of the odds ratio and significance of the other gene variables in the model was 
assessed to find evidence of confounding.  A full model was fitted containing all gene 
variables with P < 0.25 in the univariate models.  A parsimonious model was arrived at by 
eliminating the least significant gene variable and comparing the resulting model 
containing one less variable using the likelihood ratio test and the unweighted residual 
sum of squares (RSS) test (Kuss, 2002).  This process was continued until eliminating a 
variable resulted in a χ2 statistic from the likelihood ratio with a p-value less than 0.05 
which indicated the model was significantly worse fitting. 
 
Clinicians prefer to have a cut-point above which one prognosis is more likely than the 
alternative, rather than a continuous value with the likelihood of a disease outcome 
increasing as the value increases.  Receiver Operating Characteristic (ROC) analysis helps 
identify the most appropriate classification rules and was used to examine whether gene 
expression information would be useful at predicting prognosis in patients diagnosed with 
GBM.  ROC curve analysis was used to find cut-points for IHC scores that maximised the 
 - 15 - 
sensitivity and specificity of predicting prognosis in the genes that were in the final model.  
These cut-points were compared to the sensitivity and specificity of the scores in their 
original form.  IHC scores from predictive genes were combined and analysed with ROC 
curves to examine whether the combination was better at prediction that the genes 
separately. 
 
Survival analysis was used to examine the relationship between gene expression as 
measured by IHC, and survival time as this could differ from its relationship with the 
binary outcome of survival for more than 1000 days.  Survival analysis uses information 
from all time points from diagnosis until death while logistic regression only considers 
whether the subject survived for more than 1000 days.  If the expression of a gene has an 
effect on survival within the first few months after diagnosis, but not later, this would not 
be evident from logistic regression.  While long term survival is the primary focus of this 
study, it was thought that survival analysis might reveal more detailed effects of the 
expression of these genes on prognosis.   
 
The outcome variable was survival time in days, counted from the patient admission date 
for first surgery or biopsy of the tumour.  A second exploratory analysis used Kaplan 
Meier curves, incidence rates and logrank tests was carried out and categories with similar 
incident rates were merged for Cox regression analysis of the ordered categorical variables 
to ensure the ordered categorical variables were linear in the log hazard.  Univariate Cox 
regression models were fitted for each gene variable with P < 0.25 in exploratory analysis.  
A multivariate Cox regression model was fitted using the variables in the univariate 
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models and the influence of the presence of each gene on the size of the hazard ratio and 
significance of the other gene variables in the model was assessed to find evidence of 
confounding.  A parsimonious model was arrived at using a similar procedure to that for 
the logistic regression model, testing each model for the proportional hazards assumption. 
 
All analyses were carried out using Stata 8.2. 
 
3. Results 
3.1. Exploratory analysis 
The results of exploratory analysis are given in Table 1.  28 patients in the study survived 
less than 1000 days from their first surgery or biopsy and 13 survived more than 1000 
days.  Fifteen were female and 26 male with ages ranging from 26 to 62.   Histograms of 
age for the full dataset with the original three LTSs are shown in Figure 1.  In all cases, 
corresponding figures for the dataset without the three originals are given in the Appendix.  
Age was found not to be normally distributed by the Shapiro-Wilks test (P = 0.002), so a 
Mann-Whitney test was used to test for significant differences in age between the long 
term and STSs.  No significant difference in age was found (P = 0.11). 
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Table 1: Comparison of long term and STSs by age, gender, IGFBP2, IQGAP1, PTEN 
and MGMT score.  
  Frequency (% )  
  Short 
term 
Long 
term 
coeff by 
level * 
Tests for significant effects 
and trend 
Number Levels 28 13   
Gender Female 11 (73) 4 (27) 0 
 Male 17 (65) 9 (35) 0.38 Fisher’s exact P = 0.73 
IGFBP2 0 6 (60) 4 (40) 0 
(original 1 1 (12) 7 (88) 2.35 
IHC scores) 2 6 (86) 1 (14) -1.39 
 3 15 (94) 1 (6) -2.30 
Fisher’s exact P < 0.0005 
Mantel Haenszel test for trend 
P = 0.005 
IGFBP2 0&1 7 (39) 11 (61) 0 
(3 levels) 2 6 (86) 1 (14) -2.24 
 3 15 (94) 1 (6) -3.16 
Fisher’s exact P < 0.001 
Mantel Haenszel test for trend 
P = 0.0006 (0.002)#
IQGAP1 0 1 (50) 1 (50) 0 
(original 1 0 (0) 1 (100) - 
IHC scores) 2 5 (50) 5 (50) 0 
 3 7 (87) 1 (13) -1.95 
 4 15 (75) 5 (25) -1.10 
Fisher’s exact = 0.18 
Mantel Haenszel  test for trend
P = 0.10 
IQGAP1 0&1 1 (33) 2 (67) 0 
(3 levels) 2 5 (50) 5 (50) -0.69 
 3&4 22 (79) 6 (21) -2.00 
Fisher’s exact = 0.09 
Mantel Haenszel  test for trend
P = 0.04 (0.09)#
<7% 10 (100) 0 (0) - 
7-39% 7 (70) 3 (30) -1.41 
40-67% 7 (70) 3 (30) -1.41 
MGMT % 
stained nuclei 
in quartiles 
>67% 4 (36) 7 (64) 0 
Fisher’s exact = 0.013 
Mantel Haenszel  test for trend
P = 0.003 
MGMT <7% 10 (100) 0 (0) - 
(3 levels) 7-67% 14 (70) 6 (30) 17.5 
 >67% 4 (36) 7 (64) 19.0 
Fisher’s exact = 0.005 
Mantel Haenszel  test for trend
P = 0.002 (0.008)#
PTEN 0 8 (53) 7 (47) 0 Fisher’s exact P = 0.17 
IHC score 1 20 (77) 6 (23) -1.07  
   Short term Long term  
Survival time Lower quartile 255 1126  
 Median 389 1192  
 Upper quartile 752.5 1477  
Age at 1st Mean 49.1 45.8 
Surgery Stand dev 9.4 8.5 
Mann Whitney test 
P = 0.11 
* Coeff by level: the logistic regression coefficient at each level of IHC score calculated 
with the scores either in their original or final form. 
# adjusted p-value using modified Bonferroni correction in groups merged to maximise 
trend. 
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Figure 1: Frequency distribution of age at first operation in STSs and LTSs. 
 
There appeared to be no difference in the proportion of males between LTSs and STSs.  It 
was noted however that males in this study outnumbered females by around 2:1.  This was 
consistent with earlier findings of the proportion of males to females with GBMs.  
 
Fisher's exact test showed that there was a highly significant difference in IGFBP2 score 
between the LTSs and STSs with lower scores associated with long-term survival.  The 
Mantel-Haenszel test for trend showed that this followed a trend of increasing long term 
survival with decreasing IHC scores.  Logistic regression coefficients were calculated for 
each level of the IHC score.  The coefficients for levels 0 and 1 did not display a linear 
trend with levels 2 and 3 and so they were combined to give 3 levels of IHC score for 
IGFBP2 to improve the linear trend.  The linearity between IHC scores and the logit of the 
proportion of patients who were LTSs was improved with 3 levels of IHC scores.  The p-
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value for this trend was adjusted using a modified Bonferroni correction to adjust for this 
data determined cutpoint. 
 
There were only 2 patients with IQGAP1 IHC scores of 0 and only one patient with a 
score of 1 and the coefficients for levels 0, 1 and 3, 4 did not display a linear trend and so 
these scores were combined to give 3 levels of IHC score for IQGAP1.  The logistic 
regression coefficients showed a linear trend after combining the groups which was not 
significant after adjusting the p-value using a modified Bonferroni correction. 
 
There was no significant difference in PTEN IHC score between LTSs and STSs. 
 
With the percent nuclei staining for MGMT divided into quartiles there was a significant 
linear trend as measured by the Mantel Haenszel Test for Trend, but the logistic regression 
coefficients for 7-39% and 40-67% were exactly the same.  The 7-39% and 40-67% 
quartiles were combined to give a 3 level variable: <7%, 7-67% and >67% to give a linear 
relationship between categories of nuclear staining and the logit of the proportion of 
patients who were LTSs.  The p-value for this trend was adjusted using a modified 
Bonferroni correction to adjust for the data determined cutpoint. 
 
Figure 2 below and a comparison in Table 1 of the quartile and the 3 level outcomes for 
percent nuclei staining for MGMT showed that there were differences between LTSs and 
STSs.  No LTSs had less than 10% staining and most had more than 50%, while 10 of the 
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STSs had 0-5% staining.  With MGMT coded as a 3 level variable the difference between 
STSs and LTSs was highly significant using Fisher’s exact test. 
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Figure 2: Frequency distribution of % nuclei staining for MGMT in STSs and LTSs. 
 
3.2. Logistic Regression for predictors of long-term survival 
Univariate Analysis with Logistic Regression 
Table 2 gives odds ratios with 95% confidence intervals and p-values that resulted from 
univariate logistic regression with LT or ST survival as the outcome.  Gender was not 
included as it had a P > 0.25 in exploratory analysis and was not a variable of interest.  
Age and PTEN expression did not significantly predict the outcome.  IGFBP2 and MGMT 
IHC score were good predictors of LTS while IQGAP1 IHC score was just significant in 
predicting LTS.  An increase of one level in the IGFBP2 IHC score; that is an increase 
from 0 or 1 to a score of 2 or from 2 to 3, was associated with an approximately 80% 
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reduction in the odds of becoming a LTS, while a one level increase in MGMT staining 
was associated with a 6 fold increase in the odds of becoming a LTS. 
 
3.3 Fitting the baseline model 
All variables with P < 0.25 in univariate analysis were included in the baseline model.  
These were IGFBP2 (3 levels), IQGAP1 (3 levels), PTEN and MGMT (3 levels).  Age 
was also included although its univariate P = 0.28 was greater than 0.25, because it is 
usually a very strong predictor of survival and to control for differences between the ages 
of LT and STSs. 
Table 2: Odds Ratios and p-values for predictors of LTS or STS in univariate models 
compared to the multivariate baseline model. 
 Univariate Baseline multivar model 
 Odds Ratio P Odds Ratio P VIF 
IGFBP2–3 levels: 0&1, 2, 3 0.18 0.003 0.17 0.031 1.55 
IQGAP1–3 levels: 0&1, 2, 3&4 0.33 0.047 0.44 0.31 1.33 
PTEN 0.34 0.12 0.27 0.26 1.22 
MGMT-3 levels <7, 7-67, >67% 6.4 0.005 9.33 0.012 1.04 
Age (per year) 0.96 0.28 1.06 0.35 1.39 
Log likelihood   -10.79   
 
The Odds Ratios and P-values for each predictor were compared between the univariate 
and multivariate models to check for large changes in significance or odds ratios as an 
indicator of confounding or collinearity.  The variance inflation factor (VIF) was 
calculated as a measure of collinearity.  The results are shown in Table 2.  MGMT showed 
a large change in significance between the univariate and multivariate model, changing 
from P = 0.005 to P = 0.012 with its odds ratio changing from 6.4 to 9.3, a change of 46%.  
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When IGFBP2 was dropped from the baseline model the odds ratio for MGMT returned to 
its univariate value.  This indicated that there could be confounding or collinearity 
between MGMT and IGFBP2 however the value for VIF indicated that collinearity was 
not the cause.   There was also some confounding between IGFBP2 and both IQGAP1 and 
PTEN as the odds ratio for IQGAP1 changed by 30% and for PTEN by 23% and returned 
to their original values when IGFBP2 was removed, however there was again no 
indication of collinearity as measured by the VIF.  
 
To investigate this further, the relationships between IHC results were examined using 
crosstabs and Fisher’s exact test.  This is shown in Table 3.  The relationship between age 
in quartiles and IHC result was also examined, but only results for the two IHC variables 
with a Fisher’s exact test significant at the 5% level have been included in Table 3.  There 
was a significant relationship between IGFBP2 and IQGAP1.  Higher values of IQGAP1 
were associated with high values of IGFBP2.  The p-value for Fisher’s exact test was 0.02, 
so the relationship was not strong.  Because Fisher’s exact test indicated that the 
relationship between IGFBP2 and IQGAP1 was only just significant and because the VIFs 
in Table 2 were all below 2, collinearity did not seem to be a problem.   
 
There was a very strong relationship however, between age and IGFBP2 score with a p-
value of 0.008 and a just significant relationship between age and PTEN score with older 
age associated with higher scores of both. 
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Table 3:  Crosstabs of frequency.  The frequency, expected frequency and probability 
under the null hypothesis of no association between IHC scores using Fisher’s exact test. 
IGFBP2 IQGAP1 -3 level MGMT -3 level PTEN 
3 level 0 1 2 <7% 7-67 >67% 0 1 
0 3 (1.3) 
0 
(0.5) 
0 
(1.2) 
3 
(4.4) 
8 
(8.8) 
7 
(4.8) 
9 
(6.6) 
9 
(11.4) 
1 7 (4.4) 
2 
(1.7) 
1 
(3.9) 
3 
(1.7) 
3 
(3.4) 
1 
(1.9) 
1 
(2.6) 
6 
(4.4) 
2 8 (12.3) 
5 
(4.8) 
15 
(10.9) 
4 
(3.9) 
9 
(7.8) 
3 
(4.3) 
5 
(5.9) 
11 
(10.1) 
Fisher’s exact p-value = 0.02 = 0.5 = 0.2 
IQGAP1 MGMT –3 level PTEN  MGMT- 3 level 
3 level <7% 7-67 >67% 0 1 PTEN <7% 7-67 >67% 
0 1 (0.7) 
1 
(1.5) 
1 
(0.8) 
1 
(1.1) 
2 
(1.9) 0 
3 
(3.7) 
8 
(7.3) 
4 
(4.0) 
1 3 (2.4) 
3 
(4.9) 
4 
(2.7) 
4 
(3.7) 
6 
(6.3) 1 
7 
(6.3) 
12 
(12.7) 
7 
(7.0) 
2 6 (6.8) 
16 
(13.7) 
6 
(7.5) 
10 
(10.2) 
18 
(17.8) Fisher’s exact  p-value = 0.9 
Fisher’s exact p-value = 0.5 = 1.0  
Age in PTEN IGFBP2 -3 level 
quartiles  0 1 0 1 2 
<43 7 (4.0) 
4 
(7.0) 
9 
(4.8) 
0 
(1.9) 
2 
(4.3) 
43-51 5 (3.7) 
5 
(6.3) 
6 
(4.4) 
2 
(1.7) 
2 
(3.9) 
52-54 2 (3.7) 
8 
(6.3) 
1 
(4.4) 
2 
(1.7) 
7 
(3.9) 
>54 1 (3.7) 
9 
(6.3) 
2 
(4.4) 
3 
(1.7) 
5 
(3.9) 
frequency  
(expected frequency) 
Fisher’s exact p-value = 0.04  = 0.008   
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3.4. Finding the best model 
To find the most parsimonious model, the least significant variable was removed one at a 
time and the remaining model retested for fit using the likelihood ratio test.  The final 
model was also tested for fit using the residual sum of squares test.  The results are shown 
in Table 4.  Although the Hosmer Lemeshow test is the usual test of choice for model fit 
with logistic regression models, it has very poor power to reject a poorly fitting model 
with this sample size (Kuss; Hosmer and Hjort) and was unable to reject any of the 
models.  The residual sum of squares test (RSS) displays better power with sparse data 
(Kuss, 2002).   
Table 4: Assessing the fit of the models using the likelihood ratio test compared to the 
previous model and the unweighted residual sum of squares (RSS) test. 
 Likelihood ratio test RSS test 
Variables modelled -2 log likelihood Ch
2 (df) P z P 
IGFBP2,IQGAP1,MGMT,PTEN, age 25.68 - -   
IGFBP2,IQGAP1,MGMT,PTEN 26.61 0.93 (1) 0.33   
IGFBP2,IQGAP1,MGMT 27.76 1.15 (1) 0.28   
IGFBP2,MGMT 28.58 0.82 (1) 0.37 0.65 0.5 
IGFBP2 37.60 9.02 (1) 0.003   
 
From Table 4 we can see that the final model with only IGFBP2 and MGMT was the most 
parsimonious model to fit the data.  Table 5 gives the Odds Ratios, 95% confidence 
interval, coefficients and P-values for this final model.  For each increase in IGFBP2 IHC 
score (with 3 levels) there was around an 80% decrease in the odds of becoming a LTS.  
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The effect of having 7-67% compared to <7% nuclei staining for MGMT or >67% 
compared to 7-67% was around an 8 fold increase in the odds of becoming a LTS. 
 
Table 5:  Parsimonious logistic regression model for LTS or STS, with IGFBP2 and 
MGMT expression as predictors. 
 Odds ratio 95% CI coeff P 
IGFBP2 -3 levels:0&1, 2, 3 0.17 0.05-0.60 -1.76 0.006 (0.02)# 
MGMT -3 levels: <7%,7-67%,>67%) 7.6 1.5-38 2.03 0.014 (0.05)# 
c-statistic = 0.91   (Hanley and McNeil, 1982)     
# adjusted p-value using modified Bonferroni correction to adjust for groups merged to 
maximise trend. 
 
3.5. ROC analysis 
Only IGFBP2 and MGMT were considered for ROC analysis as only these two predictors 
were present in the final logistic regression model.  Figure 3A shows separate ROC plots 
for IGFBP2 and for MGMT expression with the MGMT in its original form and IGBP2 
with 3 levels.  IGFBP2 and MGMT had the same area under the curve of 0.80.  Figure 3B 
shows IGFBP2 and MGMT categorised into binary variables at the best point for 
predicting long-term survival which was between 1 and 2 of the original IHC scores for 
IGFBP2 and between 51 and 52 percent nuclei staining for MGMT.  The area under the 
curve for these binary variables was similar to the variables in their original form, 
indicating that if clinicians would like to advise their patients whether they were likely to 
become a LTS based on IHC results for these genes, choosing these as cut-offs would give 
a similar balance of sensitivity and specificity as the original scores. 
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Clinicians may also like to know if combining information from IHC scores from both 
genes is more useful in predicting which patients are likely to be LTSs than each gene 
taken separately.  To test this, a combined variable using both the IGFBP2 and MGMT 
result was created.  The combined variable IGFBP2 & MGMT had a value of 1 if a patient 
had a score of 0 or 1 for IGFBP2 and 52% or more nuclei staining for MGMT and zero 
otherwise.  The area under a ROC plot of this variable was greater than the area under the 
individual curves for binary IGFBP2 or MGMT but not significantly greater using the 
roccomp test in Stata, so this combined variable does not provide more information for 
clinicians.  Table 6 shows that IGFBP 2 has better sensitivity; MGMT has better 
specificity while the combined variable has worse sensitivity and better specificity than 
using the variables separately.  In this case sensitivity means correctly predicting which 
patients will become LTSs and specificity means correctly predicting who will become a 
STS.  From the patients’ perspective it is preferable to be able to predict LTSs, making 
IGFBP2 expression status the better clinical predictor. 
 
Table 6: Sensitivity, specificity, positive and negative predictive value and % correctly 
predicted, using IGFBP2, MGMT or a combined variable obtained by multiplying a 
binary variable from IGFBP2 (scores of 0 &1 versus scores of 2 & 3) by a binary MGMT 
variable (less than or more than 52% staining). 
 Sensitivity Specificity % correct 
IGFBP2 -3 levels: 0&1, 2, 3 84.6% 75.0% 78.1% 
IGFBP2 –binary: 0&1, 2&3 84.6% 75.0% 78.1% 
MGMT -3 levels: <7%, 7-67%, >67% 53.9% 85.7% 75.6% 
MGMT -binary: <52%, ≥52%  76.9% 81.5% 80.0% 
IGFBP2 (bin) & MGMT (bin) 69.2% 92.6% 85.0% 
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 3.6. Survival Analysis 
Survival analysis uses survival time as the outcome with information from patients with 
the shortest to those with the longest interval from diagnosis until death.  This compares to 
logistic regression which only considers whether the subject was a LTS or a STS.  
Because of this, the relationship between predictors and outcome may not necessarily be 
the same since the expression levels of a gene may have one effect on the risk of death 
within the first months after diagnosis and a different effect later if the patient survives 
these first months. While the primary interest of this project is on predictors of long term 
survival it was thought that survival analysis might reveal more detailed effects of the 
expression of these genes on prognosis.  An additional exploratory analysis was carried 
Figure 3: ROC plots showing sensitivity and 1-specificity of the classification of patients 
as LTSs or STSs based on their IGFBP2 and MGMT immunohistochemistry.  Plot A 
shows all levels of MGMT and 3 levels of IGFBP2.  The values for IGFBP2 are in reverse 
order to allow them to be plotted on the same graph.  Plot B has MGMT categorised into 
<52% or ≥52% stained nuclei and IGFBP2 into 0 or 1 compared to 2 or 3, again in reverse 
order.   
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out using Kaplan Meier curves and incidence rates to find which IHC scores had similar 
survival curves.  This is shown in Table 7. 
 
3.7: Exploratory Analysis 
 
Table 7:  Results of exploratory survival analysis. 
   Incidence Logrank test 
Variable Level No. rate/day Chi2 (df) P 
IGFBP2 (3 levels) 0, 1 18 0.0009 5.80 (2) 0.055 
 2 7 0.0018   
 3 16 0.0016   
IGFBP2 (binary) 0, 1 18 0.0009 5.80 (1) 0.016 
 2, 3 23 0.0016  (0.06)# 
IQGAP1 (3 levels) 0, 1 3 0.0005 1.87 (2) 0.39 
 2 10 0.0012   
 3, 4 28 0.0014   
IQGAP1 (binary) 0, 1 3 0.0005 1.71 (1) 0.19 
 2, 3, 4 38 0.0013  (0.8)# 
MGMT (quartiles) < 7% 10 0.0031 21.35 (3) 0.0001 
 7-39% 10 0.0012   
 40-67% 10 0.0013   
 >67% 11 0.0007   
MGMT (3 levels) <7% 10 0.0031 20.68 (1) <0.0001 
 7-67% 20 0.0012  (0.0001)# 
 >67% 11 0.0007   
PTEN 0 15 0.0010 1.25 0.26 
 1 26 0.0013   
Gender Female 15 0.0014 0.70 (1) 0.40 
 Male 26 0.0011   
Age (in quartiles) <43 11 0.0009 3.13 (3) 0.37 
 43-51 10 0.0012   
 52-54 10 0.0016   
 >54 10 0.0014   
# adjusted p-value using modified Bonferroni correction to adjust for groups merged to 
maximise trend. 
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From the incidence rates and Kaplan Meier curves it could be seen that there was a 
difference in survival between IGFBP2 IHC scores of levels 0 and 1 compared to levels 2 
and 3 but none between level 2 and 3, so a binary form of IGFBP2 was used for survival 
analysis.  IQGAP1 had a difference in exploratory analysis between levels 0 and 1 
compared to 2, 3 and 4, so again a binary form would have been better to use for survival 
analysis.  However as there were only three subjects with level 0 or 1 scores, three levels 
of score were used as in the previous section.   
IHC score = 0 or 1
core = 2
IHC score = 3 
 
Figure 4: Kaplan Meier Curves for IGFBP2 with three or two levels of IHC score. 
Figure 5: Kaplan Meier Curves for IQGAP1 with three or two levels of IHC score. 
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Figure 6: Kaplan Meier curves for MGMT percentage stained nuclei, divided at quartiles 
or divided into3 levels at <7%, 7-67% and >67%. 
 
Exploratory analysis of MGMT showed a difference in survival between <7% stained 
nuclei compared to 7-67% and between 7-67% compared to >67%, with no difference 
between 7-39% and 40-67%.  With these two quartiles merged to give 3 levels: <7%, 7-
67% and >67% stained nuclei the difference in survival between the groups was clear so 
as before the 3 level form of MGMT was used. 
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Figure 7: Kaplan Meier curves for PTEN IHC score  
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As with the earlier analysis for predictors of long term survival, there was no influence 
apparent from PTEN IHC score, gender or age on survival time in exploratory analysis.   
female
male
Figure 8: Kaplan Meier curves for gender and age. 
 
 3.8. Fitting the baseline multivariate model 
All variables with P < 0.25 in univariate analysis using the logrank test were included in 
the baseline model.  These were IGFBP2 (binary), IQGAP1 (3 levels), and MGMT (3 
levels) based on the results of the previous section.  Age was included although its 
univariate p-value was 0.30, because it is usually a very strong predictor of survival.  
PTEN with P = 0.27 was not included. 
 
The Hazard Ratios and P-values for each predictor were compared between the univariate 
and multivariate models to check for confounding.  The results are shown in Table 8.  The 
predictor with the greatest changes in the size of the Hazard Ratio were IGFBP2 which 
changed from 2.32 to 1.56 a change of 33% indicating confounding between IQGAP1 and 
IGFBP2 due to correlation between the two variables which was increased when IGFBP2 
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was expressed as a binary variable.  The p-value for IGFBP2 also went from slightly 
significant at P = 0.017 to not significant at P = 0.9 in the presence of IQGAP1.  However 
from the size of the VIFs there did not appear to be any serious collinearity. 
 
Table 8: Hazard Ratios and P-values using predictors of survival time in univariate models 
compared to the multivariate baseline model.  
 Univariate Baseline multiv model 
 Hazard  Ratio P 
Hazard 
Ratio P VIF 
IGFBP2 -binary: 0&1, 2&3 2.32 0.019 1.56 0.88 1.75 
IQGAP1 -3 levels: 0&1, 2, 3&4 1.42 0.20 1.29 0.73 1.30 
MGMT -3 levels: <7%, 7-67%, >67% 0.34 <0.0001 0.34 0.001 1.08 
Age 1.02 0.30 1.00 0.98 1.32 
Log likelihood   -99.02   
 
 
3.9. Finding the best model 
To find the most parsimonious model, the least significant variable was removed one at a 
time and the remaining model retested for fit using the likelihood ratio test.  The global 
proportional hazards assumption was tested for each model.  The results are shown in 
Table 9.   
 
The final model with only MGMT was the most parsimonious model that fitted the data.  
The Hazard Ratio was 0.34 (95% confidence interval: 0.19-0.60) which meant patients 
with 7-67% MGMT staining had a 65% reduction in the instantaneous risk of death from 
GBM compared to patients with <7% staining.  Likewise patients with >67% staining had 
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a similar reduction of risk when compared to patients with 7-67% staining.  The p-value 
was 0.0001 and the adjusted p-value 0.0004 using a modified Bonferroni to adjust for 
optimizing the cutpoint to maximize trend.  
 
Table 9: Assessing the fit of the models using the likelihood ratio test compared to the 
previous model, and global test of the proportional hazards assumption using Schoenfeld 
residuals. 
 Likelihood ratio test Test of global proportional hazards assumption 
Variables modelled -2 log likelihood Ch
2 (df) P Ch2 (df) P 
IGFBP2,IQGAP1,MGMT, age 198.03 - - 2.33 (4) 0.67 
IGFBP2,IQGAP1,MGMT 198.03 0.00 (1) 1.0 2.04 (3) 0.56 
IGFBP2,MGMT 198.57 0.54(1) 0.46 0.34 (2) 0.84 
MGMT 202.21 3.64 (1) 0.056 0.44 (1) 0.50 
 
For the results of analysis without the original three LTSs, see the Appendix.
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4. Discussion 
The data have been analysed using both the original dataset including the original three 
LTSs who prompted the study, and in the dataset without these the original patients.  
Logistic regression and ROC analysis with survival for more than 1000 days as the 
outcome were used to find proteins whose over- or under-expression as measured by IHC 
were able to predict long term survival in GBM patients.  Cox regression analysis was 
used to find which proteins were able to predict survival time.   
 
These methods gave slightly different results.  Patients with low IGFBP2 
immunohistochemistry scores and/or a high percentage of nuclei staining for MGMT in 
tumour sections taken at initial biopsy or surgery were more likely to survive for more 
than 1000 days.  Having an IHC score of 2 for IGFBP2 compared to a score of 0 or 1, or a 
score of 3 compared to 2, reduced the odds a patient will survive for more than 1000 days 
by 85%.  Having more than 7-67% MGMT stained nuclei compared to less than 7% or 
more than 67% compared to 7-67%, increased the odds of surviving more than 1000 days 
by around 8 fold.  However, the best predictor of survival time as opposed to survival for 
more than 1000 days was having a high percentage of nuclei staining for MGMT in 
multivariate analysis.  Having >7% staining or more than 67% staining reduced the 
instantaneous risk of dying by 65% when compared to <7% or 7-67% respectively.  
Patients with less than 7% staining had a particularly poor prognosis with a median 
survival time of only 250 days. 
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Considering the IGFBP2 IHC score in these patients as well did not significantly improve 
the ability to predict survival time.  MGMT may be more significant in survival analysis 
because the survival curves for IGFBP2 only show a better outcome for subjects with low 
IHC scores after 250 days.  Before 250 days after diagnosis, subjects with IGFBP2 scores 
of 0 or 1 have worse survival than those with higher scores.  This contrasts with the 
Kaplan Meier curves for MGMT which show better survival throughout in patients with 
higher percentages of MGMT staining.  This was not apparent when looking at whether a 
patient is likely to become a LTS as by 1000 days the difference in survival between 
patients with low compared to high IHC scores for IGFBP2 was very large.  The primary 
aim of this project was to find predictors of LTS, and both IGFBP2 and MGMT protein 
expression are the best at this, but it was interesting that patients with low levels of 
IGFBP2 expression have a poorer prognosis for the first 250 days after diagnosis and so it 
was not as good a predictor of the instantaneous risk of death as measured by Cox 
regression as MGMT protein expression. 
 
An advantage of survival analysis over logistic regression modelling in this situation is 
that the Kaplan Meier curve reveals such changes in risk over time and so provides a more 
detailed picture of the relationship between the explanatory variables and the risk of death.  
The Kaplan-Meier curve requires few assumptions and is easy to calculate but is 
inefficient compared to parametric survival estimators such as Cox regression.  Cox 
regression and logistic regression typically produce the same p-values and very similar 
regression coefficients when used to analyse the same data with large N (Moriguchi et al, 
1993), however both Cox regression and logistic regression are prone to type I and type II 
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errors with small numbers of events per variable (EPV) and Cox regression is more 
sensitive than logistic regression to this (Vittinghoff and McCulloch, 2006).  This limits 
the usefulness of Cox regression with this data.  In our study, EPV is near the limit at 
which serious problems can be expected with logistic regression and well within the area 
where serious problems can be expected with Cox regression.  See the limitations section 
for more on this. 
 
Clinicians need to be able to advise their patients about the likely course of their disease.  
The prognosis for patients diagnosed with GBM is never good, but since some patients do 
live for three years or more after diagnosis, clinicians are likely to be interested in whether 
studies such as this can help predict which patients will live longer than the median GBM 
patient.  ROC analysis gives the sensitivity and specificity of predicting an event such as 
LT survival.  This study has shown that IGFBP2 has better sensitivity for predicting LT 
survival while MGMT has better specificity.  Since it is better from the patients’ point of 
view to correctly predict who will become a LTS than to correctly predict who will 
become a STS, this makes IGFBP2 the better predictor for the clinician.  However this 
should be tempered by the observation that some patients with low levels of IGFBP2 
expression have worse survival in the first year after diagnosis.  This effect should be 
taken into account by clinicians before using low IHC expression for IGFBP2 to predict 
the likelihood of a patient becoming a LTS. 
 
The over-expression of IGFBP2 in cancer and its association with poor prognosis is well 
established, both in GBMs and many other tumour types; however the molecular 
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mechanisms by which IGFBP2 enhances tumour cell growth and increases tumorigenicity 
remain undefined (Wang et al, 2003).  A number of studies have shown causal links 
between the level of expression of IGFBP2 and levels of expression of other genes 
upregulated in GBMs.  Wang et al (2003) found MMP2 over-expression when IGFBP2 
was over-expressed in cell lines and Fukushima et al (2007) found CD4 expression could 
be could suppressed by under expressing IGFBP2.  Zhou et al (2005) also found 
significant correlation between the expression of IGFBP2 and MMP2 in gliomas.  In 
addition they found significant correlation between IGFBP2 expression and VEGF 
(vascular endothelial growth factor) expression in the same study.  In our study we found 
that IGFBP2 expression correlates strongly with IQGAP1 expression, another gene that 
appears to be involved in invasiveness of tumours.  IGFBP2 appears to be a central player 
in controlling a number of genes promoting the invasiveness of GBMs. 
 
There is a strong relationship between age and levels of both IGFBP2 and PTEN 
expression with high levels of expression of both these genes found in GBMs from older 
patients.  Age over 60 years is strongly associated with poor prognosis and high IGFBP2 
expression levels is also associated with poor prognosis (Scott et al, 1999), so the finding 
that IGFBP2 expression correlates with age is interesting and could be part of the reason 
for poorer survival in older patients.  However higher expression of PTEN, according to 
earlier findings should be associated with a better prognosis, while older age is associated 
with a worse prognosis.  Park et al (2002) found that the introduction of the wild-type 
PTEN genes reduced invasion invitro, and Zhou et al (2005), found that patients with high 
levels of PTEN mRNA expression as measured by quantitative PCR, were more likely to 
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have favourable outcomes.  However in this study no association between PTEN protein 
expression and survival time was found, either in univariate or multivariate analysis.  It 
could be that the relationship between high levels of PTEN expression and longer survival 
is only seen in older patients who were not included in this study or alternatively that the 
increased mRNA expression is not reflected in protein levels as measured by IHC. 
 
Higher levels of protein expression of MGMT were significantly associated with better 
survival for more than 1000 days.  However Hegi et al (2005) found that MGMT promoter 
methylation, which would be expected to result in lower MGMT expression, was a 
favourable prognostic factor for longer survival irrespective of treatment and also was 
associated with a more favourable response of patients to temozolomide and radiotherapy 
treatment.  However low levels of expression of MGMT would also be expected to result 
in an increased frequency of mutations, particularly in these patients who are undergoing 
radiotherapy as well as chemotherapy.  This may lead to mutations that give rise to more 
aggressive tumour behaviour.  This may be having the predominant effect in this study. 
 
The expression of MGMT does not correlate with IGFBP2 expression and so MGMT 
represents an independent gene or gene pathway associated with prognosis.  In biological 
terms it means that the control of IGFBP2 expression and MGMT expression are 
independent of each other.   
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4.1 Analysis without the original Log Term Survivors. 
IQGAP1 expression as measured by IHC was only a significant predictor of long term 
survival in the dataset that included the original three LTSs and then only with a p-value 
of 0.047.  Since IQGAP1 expression was one of the variables found to be down-regulated 
in two of the original three long-term survivors, the fact that this is not confirmed in the 
larger group without these originals may mean the result of the analysis in the data set 
containing the originals was biased by including them.  This affected the analysis in 
several ways.  Although there appeared to be a linear trend between IQGAP1 score and 
LTS with the original three patients, this trend disappeared without them.  Kaplan Meier 
curves appeared to show a weak effect of IQGAP1 IHC score on survival but this 
disappeared without the three original LTSs.  Since there was a relationship between the 
protein expression of IQGAP1 and IGFBP2, any apparent effect of IQGAP1 may be through 
this relationship rather than a direct effect of IQGAP1 on tumour growth and survival. 
 
Two of the original three LTSs were over 55 years of age while the average age of the 
other LTSs was 44 and so another way in which the inclusion of the original LTSs 
affected the analysis was through age.  There was a significant difference in age between 
the LTSs and STSs without the original three LTSs using the Mann Whitney test, but not 
using logistic regression. 
 
Both IGFBP2 and MGMT became less significant predictors of LTS in logistic regression 
without the three originals, presumably because of the loss of power associated with there 
being three fewer events to model.  However IGFBP2 became more significant in survival 
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analysis without the original three, possibly because one of these three was the only LTS 
to have a score of 3 for IGFBP2. 
  
4.2 Limitations 
Small studies such as the one conducted for this project have disadvantages from the point 
of view of statistical analysis and the subsequent interpretation of results.  Both logistic 
regression and Cox regression have problems when there are small numbers of events per 
variable (EPV).  There were only 13 events (LTSs) in this study or 10 if we exclude the 
original LTSs.  With 2 variables in the final model, we are at the limit below which one 
can expect problems with type I error in logistic regression.  Power falls steadily as the 
number of EPV decreases from 20 to 10 in logistic regression and then falls sharply below 
10 EPV leading to problems increasing type II error rates (Vittinghoff and McCulloch, 
2006) and (Peduzzi et al, 1996).  These problems are more extreme with Cox regression 
and occur at higher EPV.  In our study, EPV is near the limit at which serious problems 
can be expected with logistic regression and well within the area where serious problems 
can be expected with Cox regression.  However the most likely effect of small EPV on 
logistic regression analysis is a conservative conclusion due to lack of power and so 
significant results are likely to be found to even more strongly significant when repeated 
with more EPV.  With Cox regression the problems are likely to be more extreme and so 
these results should be treated with caution.   
 
The study described in this project used all the subjects available through the Kolling 
Institute’s Brain Tumour Bank and the Sydney Neuro-Oncology Group at the time the 
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immuno-histochemistry was carried out.  As time passes, more patients will become 
available and still more patients can be recruited by collaborating with other institutions, 
making a larger study feasible.  My former supervisor, Kerrie McDonald, is presently 
seeking funding for a larger study, with more subjects and using more genetic markers.   
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Appendix: Analysis without the original three LTSs. 
3.1. Exploratory analysis 
The results of exploratory analysis without the original three LTSs are given in Appendix 
Table 1.  The results were similar to those with the three originals except a significant 
difference in age was found (P = 0.03) with the LTSs about five years younger on average 
than the STSs.   
 
Another difference was that the linear trend between long term survival and IQGAP1 
score was worse in the dataset without the original LTSs and was still not present with 3 
levels of IQGAP1 score. 
 
A comparison of Figure 1 and Appendix Figure 1 shows the reason for the significant 
difference in age between LTSs and STSs: two of the original three LTSs were over 55 
years of age. 
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Appendix Table 1: Comparison of LTS and STSs by age, gender, IGFBP2, IQGAP1, 
PTEN and MGMT score without the original 3 LTSs.  
  Frequency (% )  
  Short term Long term 
coeff by 
level* 
Tests for significant effects and 
trend 
Number  28 10  
Gender Female 11 (84.6) 2 (15.4) 
 Male 17 (68) 8 (32) 
 Fisher’s exact = 0.44 
IGFBP2 0 6 (60) 4 (40) 0 
(original 1 1 (16.7) 5 (83.3) 2.01 
IHC scores) 2 6 (85.7) 1 (14.3) -1.39 
 3 15 (100) 0 (0) - 
Fisher’s exact P < 0.0001 
Mantel Haenszel test for trend 
P = 0.003 
IGFBP2 0&1 7 (43.7) 9 (56.3) 0 
(3 levels) 2 6 (85.7) 1 (14.3) -2.04 
 3 15 (100) 0 (0) - 
Fisher’s exact P < 0.001 
Mantel Haenszel test for trend 
P = 0.0004 (0.002)# 
IQGAP1 0 1 (50) 1 (50) 0 
(original 1 0 (0) 0 (0) - 
IHC scores) 2 5 (55.6) 4 (44.4) -0.22 
 3 7 (87.5) 1 (12.5) -1.95 
 4 15 (78.9) 4 (21.1) -1.32 
Fisher’s exact = 0.34 
Mantel Haenszel  test for trend 
P = 0.18 
IQGAP1 0&1 1 (50) 1 (50) 0 
(3 levels) 2 5 (55.6) 4 (44.4) -0.22 
 3&4 22 (81.5) 5 (18.5) -1.48 
Fisher’s exact = 0.18 
Mantel Haenszel  test for trend 
P = 0.10 (0.4)# 
<7% 10 (100) 0 (0) - 
7-39% 7 (77.8) 2 (22) -1.66 
40-67% 7 (77.8) 2 (22) -1.66 
MGMT % 
stained nuclei 
in quartiles 
>67% 4 (40) 6 (60) 0 
Fisher’s exact = 0.019 
Mantel Haenszel  test for trend 
P = 0.004 
MGMT <7% 10 (100) 0 (0) - 
(3 levels) 7-67% 14 (77.8) 4 (22) 17.3 
 >67% 4 (40) 6 (60) 18.9 
Fisher’s exact = 0.001 
Mantel Haenszel  test for trend 
P = 0.009 
PTEN 0 8 (57.1) 6 (42.9) Fisher’s exact P = 0.08 
IHC score 1 20 (83.3) 4 (16.7)   
   Short term Long term  
Survival time Lower quartile 255 1126  
 Median 389 1184.5  
 Upper quartile 752.5 1214  
Age at 1st Mean 49.1 44.4 
surgery Stand dev 9.4 6.6 
Mann Whitney test 
P = 0.03 
* Coeff by level: the logistic regression coefficient at each level of IHC score with the 
scores in their original or final form. 
# p-value with modified Bonferroni correction in groups merged to maximise trend. 
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Appendix Figure 1: Frequency distribution of age at first operation in STSs and LTSs 
without the original LTSs. 
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Appendix Figure 2: Frequency distribution of % nuclei staining for MGMT in STSs and 
LTSs without the original LTSs.  
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3.2. Logistic Regression for predictors of long-term survival 
Univariate Analysis with Logistic Regression 
Appendix Table 2 gives the results of univariate logistic regression.  They were very 
similar to those with the original LTSs, except IQGAP is no longer significant either in its 
original form with five levels of score or with three levels of score.  Age was not 
significantly different between the two groups using this method of analysis. 
 
3.3. Fitting the baseline model 
Appendix Table 2: Odds Ratios and Ps for predictors of long term or short term survival in 
univariate models compared to the multivariate baseline model.  
 Univariate Baseline multivar model 
 Odds Ratio P Odds Ratio P VIF 
IGFBP2 – 3 levels: 0&1, 2, 3 0.08 0.013 0.05 0.035 1.56 
IQGAP1 – original scores 0.65 0.19 1.10 0.86 1.24 
IQGAP1 – 3 levels: 0&1, 2, 3&4   0.38 0.12    
PTEN 0.27 0.086 0.16 0.17 1.40 
MGMT – 3 levels: <7%, 7-67%, >67% 7.36 0.007 7.5 0.041 1.07 
Age 0.94 0.16 1.10 0.22 1.66 
Log likelihood   -9.42   
 
In the baseline model containing all variables with p-values <0.25, the results were very 
similar to those with the original LTSs.  IQGAP1 has been used in its original form as 
merging scores made no difference to the linearity of trend. 
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 Appendix Table 3: Crosstabs of frequency.  Shows the frequency, expected frequency and 
probability under the null hypothesis of no association between IHC scores using Fisher’s 
exact test. 
 IQGAP1-3 level MGMT-3 level PTEN 
IGFBP2 0 1 2 <7 7-67% >67% 0 1 
0 2 (0.8) 
6 
(3.8) 
8 
(11.4) 
3 
(4.2) 
6 
(7.6) 
7 
(4.2) 
8 
(5.9) 
8 
(10.1) 
1 0 (0.4) 
2 
(1.7) 
5 
(5.0) 
3 
(1.8) 
3 
(3.3) 
1 
(1.8) 
1 
(2.6) 
6 
(4.4) 
2 0 (0.8) 
1 
(3.6) 
14 
(10.7) 
4 
(3.9) 
9 
(7.1) 
2 
(3.9) 
5 
(5.5) 
10 
(9.5) 
Fisher’s exact p-value = 0.07 = 0.3 = 0.3 
IQGAP1 MGMT-3 level PTEN  MGMT-3 level 
3 level <7 7-67% >67% 0 1 PTEN <7 7-67% >67% 
0 1 (0.5) 
0 
(0.9) 
1 
(0.5) 
1 
(0.7) 
1 
(1.3) 0 
3 
(3.7) 
7 
(6.6) 
4 
(3.7) 
1 3 (2.4) 
2 
(4.3) 
4 
(2.4) 
3 
(3.3) 
6 
(5.7) 1 
7 
(6.3) 
11 
(11.4) 
6 
(6.3) 
2 6 (7.1) 
16 
(12.8) 
5 
(7.1) 
10 
(9.9) 
17 
(17.1) Fisher’s exact  p-value = 0.9 
Fisher’s exact p-value = 0.1 = 1.0  
Age in PTEN IGFBP2-3 level 
quartiles  0 1 0 1 2 
<43 7 (3.7) 
3 
(6.3) 
8 
(4.2) 
0 
(1.8) 
2 
(3.9) 
43-51 5 (3.7) 
5 
(6.3) 
6 
(4.2) 
2 
(1.8) 
2 
(3.9) 
52-54 2 (3.7) 
8 
(6.3) 
1 
(4.2) 
2 
(1.8) 
7 
(3.9) 
>54 0 (2.9) 
8 
(5.1) 
1 
(3.4) 
3 
(1.5) 
4 
(3.2) 
frequency  
(expected frequency) 
Fisher’s exact p-value = 0.008  = 0.007   
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The relationship between the IHC variables was similar to those with the original LTSs.  
However the relationship between IGFBP2 and IQGAP1 was no longer significant (p-
value = 0.07).  The association between the IHC scores and age in quartiles is also similar 
with only PTEN and IGFBP2 having a significant association, but now the relationship 
between PTEN and age is highly significant with a p-value for Fisher’s exact test of 0.008. 
 
3.4. Finding the best model 
Appendix Table 4: Assessing the fit of the models using the Likelihood ratio test and the 
unweighted residual sum of squares test (RSS). 
 Likelihood ratio test RSS test  
Variables modelled -2 log likelihood Ch
2 (df) P z P 
IGFBP2,IQGAP1,MGMT, 
PTEN, age 18.83 - -   
IGFBP2,MGMT,PTEN,age 18.87 0.04 (1) 0.84   
IGFBP2,MGMT,PTEN 20.45 1.58 (1) 0.21   
IGFBP2,MGMT 21.59 1.14 (1) 0.29 0.31 0.76 
IGFBP2 28.08 6.49 (1) 0.01   
 
The final model with only IGFBP2 and MGMT was the same as with the original LTSs.  
Appendix Table 5 gives the Odds Ratios, 95% confidence interval, coefficient and P-
values for this final model.  The effect of each increase in IGFBP2 IHC score was slightly 
greater than with the originals, giving a 90% decrease in the odds of becoming a LTS 
while the effect of having 7-67% compared to <7% or >67% compared to 7-67% nuclei 
staining for MGMT was slightly smaller than with the original LTSs giving around a 6 
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fold increase in the odds of becoming a LTS.  The p-values were less significant than with 
the original LTSs probably due to reduced power with smaller numbers. 
 
Appendix Table 5:  Parsimonious logistic regression model for LTS or STS, with IGFBP2 
and MGMT expression as predictors. 
 Odds ratio 95% CI coeff P 
IGFBP2 -3 levels:0&1, 2, 3 0.096 0.013-0.71 -2.34 0.02 
MGMT -3 levels: <7%, 7-67%, >67%) 6.4 1.2-34 1.85 0.03 
c-statistic = 0.93     
 
3.5. ROC analysis 
Appendix Figure 3 shows ROC plots for IGFBP2 and for MGMT expression without the 
original LTSs with IGFBP2 with three levels and MGMT scores in their original form also 
and categorised as binary variables at the best value for predicting LTS.  IGFBP2 had 
slightly better area under the ROC curve (AUC) than with the original LTSs in both 
forms.  The variable formed by multiplying the binary IGFBP2 and MGMT variables also 
gave a slightly better AUC than with the original long term survivors: 0.86 compared to 
0.81.   
 
Sensitivity using both IGFBP2 and MGMT to predict who will become a LTS has 
improved quite a bit without the original LTSs.  See Appendix Table 6.  IGFBP2 has 
sensitivity of 90% both as a 3 level and as a binary variable, up from 85% with the 
original LTSs.  The sensitivity of MGMT has also improved slightly and the combined 
IGFBP2 and MGMT binary variable has improved sensitivity from 70% to 80%.  
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Specificity is unchanged by the removal of the original LTSs.  IGFBP2 is still the best at 
  
predicting who will become a LTS using sensitivity. 
ppendix
Sensitivity Specificity % correct 
IGFBP2 -3 levels: 0&1, 2, 3 90.0% 75.0% 79.0% 
A  Table 6: Sensitivity and specificity and % correctly predicted, achieved using 
IGFBP2 and MGMT and a combined variable obtained by multiplying a binary variable 
from IGFBP2 (scores of 0 &1 versus scores of 2 & 3) by a binary MGMT variable (less 
than or more than 52% staining). 
 
IGFBP2 -binary: 0&1, 2&3 
, >67% 
 
90.0% 75.0% 79.0% 
MGMT -3 levels: <7%, 7-67% 60.0% 85.7% 79.0% 
MGMT -binary: <52%, ≥52% 80.0% 81.5% 81.1% 
IGFBP2 (bin) & MGMT (bin) 80.0% 92.6% 89.2% 
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Appendix Figure 3: ROC plots showing sensitivity and 1-specificity of the classification of 
patients as LTSs or STSs based on their IGFBP2 and MGMT immunohistochemistry.  Plot 
A shows all levels of MGMT and 3 levels of IGFBP2.  The values for IGFBP2 are in 
reverse order to allow them to be plotted on the same graph.  Plot B has MGMT categorised 
into <52% or ≥52% stained nuclei and IGFBP2 into 0 or 1 compared to 2 or 3, again in 
reverse order. 
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3.6. Survival Analysis . 
3.7: Exploratory Analysis 
Appendix Table 7:  Results of exploratory survival analysis. 
   incidence Logrank test 
Variable Level No. rate/day Chi2 (df) P 
IGFBP2 (3 levels) 0, 1 16 0.0009 8.16 (2) 0.017 
 2 7 0.0018   
 3 15 0.0019   
IGFBP2 (binary) 0, 1 16 0.0093 7.37 (1) 0.007 
 2, 3 22 0.0019  (0.03)# 
IQGAP1 (3 levels) 0, 1 2 0.0053 1.56 (2) 0.46 
 2 9 0.0012   
 3, 4 27 0.0015   
IQGAP1 (binary) 0, 1 2 0.0053 1.15 (1) 0.28 
 2, 3, 4 36 0.0014  (1.0)# 
MGMT (in quartiles) < 7% 10 0.0031 17.23 (3) 0.0006 
 7-39% 9 0.0012   
 40-67% 9 0.0015   
 >67% 10 0.0009   
MGMT (3 levels) <7% 10 0.0031 20.68 (1) 0.0002 
 7-67% 18 0.0013  (0.0008)#
 >67% 9 0.0009   
PTEN 0 14 0.0011 2.57 (1) 0.11 
 1 24 0.0016   
Gender Female 13 0.0016 1.09 (1) 0.30 
 Male 25 0.0013   
Age (in quartiles) <43 10 0.0010 6.60 (3) 0.086 
 43-51 10 0.0012   
 52-54 10 0.0016   
 >54 8 0.0023   
# p-value with modified Bonferroni correction in groups merged to maximise trend. 
 
Without the original LTSs IGFBP2 became a more significant predictor of survival by the 
logrank test, but still showed worse survival in the first year after diagnosis with low 
IGFBP2 scores.  There were only two subjects remaining with IQGAP1 scores of 0 or 1.  
See Appendix Table 7 and Figure 5.   
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Appendix Figure 4: Kaplan Meier Curves for IGFBP2 with 3 or 2 levels of IHC score. 
 
ppendix
Appendix Figure 6: Kaplan Meier curves for MGMT percentage stained nuclei, divided at 
A  Figure 5: Kaplan Meier Curves for IQGAP1 with 3 or 2 levels of IHC score.  
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Appendix Figure 7: Kaplan Meier curves for PTEN IHC score  
Appendix Figure 8: Kaplan Meier curves for gender and age. 
 
3.8. Univariate Analysis using Cox Regression 
 
Survival analysis was carried out using Cox regression.  The results are given in Appendix 
Table 8.  IGFBP2 has been analysed as a binary variable and IQGAP1 and MGMT with 
three levels as in the analysis with the three originals.   
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Compared to the results with the original LTSs, IGFBP2 was more significant and MGMT 
was slightly less significant.  Each increase in IGFBP2 expression as measured by a binary 
IHC score resulted in an almost 3 fold increase in the risk of death while having 7-67% 
nuclei staining for MGMT compared to <7% or >67% compared to 7-67% resulted in a 
60% fall in the risk of death.   
 
3.9. Fitting the baseline multivariate model 
All variables with P < 0.25 in univariate analysis were included in the baseline model.  
These were IGFBP2 (binary), IQGAP1 (3 levels), and MGMT (3 levels), PTEN and age.  
Appendix Table 8: Hazard Ratios and P-values using predictors of survival time in 
univariate models compared to the multivariate baseline model. 
 Univariate Baseline multivar model 
 Hazard Ratio P 
Hazard 
Ratio P VIF 
IGFBP2-binary: 0&1, 2&3 2.78 0.008 1.77 0.30 1.81 
IQGAP1-3 levels: 0&1, 2, 3&4 1.47 0.23 1.17 0.71 1.23 
MGMT– 3 levels: <7%, 7-67, >67% 0.37 0.001 0.40 0.005 1.11 
PTEN 1.80 0.11 1.72 0.22 1.40 
Age 1.03 0.20 0.98 0.47 1.85 
Log likelihood   -91.14   
 
The Hazard Ratios and Ps for each predictor were compared between the univariate and 
multivariate models to check for confounding.  The results are shown in Table 8.  The 
predictor with the greatest change in the size of the Hazard Ratio was in IGFBP2 which 
changed by 36%, followed by IQGAP1 which changed by 20%.  This indicated 
confounding of IQGAP1 by IGFBP2 and of IGFBP2 by MGMT due to a significant 
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relationship between the IQGAP1 and IGBP2 in this form (P = 0.45).  The VIF are larger 
than before but still not large enough to indicate serious collinearity. 
3.10. Finding the best model 
To find the most parsimonious model, the least significant variable was removed one at a 
time as before.  The results are shown in Table 9.  As with the dataset with the original 
three long term survivors, the final model had only MGMT as a predictor of survival time.  
Compared to patients with <7% nuclei stained for MGMT, those with 7-67% staining had 
a 60% reduction in the instantaneous risk of death from GBM and a similar reduction was 
seen in patients with >67% staining compared to 7-67%. 
 
Appendix Table 9: Assessing the fit of the models using the Likelihood ratio test 
compared to the previous model, and global test of the Proportional Hazards Assumption 
using Schoenfeld Residuals. 
 Likelihood ratio test 
Test of global 
proportional 
hazards assumption
Variables modelled -2 log likelihood Ch
2 (df) P Ch2 (df) P 
IGFBP2,IQGAP1,MGMT,PTEN,age 182.29 - - 5.07 (5) 0.41 
IGFBP2,MGMT,PTEN, age 182.44 0.15 (1) 0.70 3.63 (4) 0.46 
IGFBP2,MGMT,PTEN 182.95 0.51 (1) 0.48 2.64 (3) 0.45 
IGFBP2,MGMT 183.88 0.93 (1) 0.33 2.71 (2) 0.26 
MGMT 187.11 3.23 (1) 0.07 1.11 (1) 0.29 
 
Appendix Table 10:  Final Cox regression model for LTS or STS with IGFBP2 and 
MGMT expression as predictors. 
 Hazard ratio 95% CI P 
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MGMT– 3 levels: <7%, 7-67%, >67% 0.37 0.21-0.67 0.001 (0.004)# 
# p-value with modified Bonferroni correction in groups merged to maximise trend. 
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